Fierce Pharma
FEBRUARY 8, 2024
Thursday, when senators questioned three Big Pharma CEOs about the high price of drugs in the U.S., Health, Education, Labor and Pensions (HELP) committee chairman Bernie Sanders, I-Vermont, put th | CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.
MedCity News
FEBRUARY 8, 2024
The integration of AI technologies holds promise for enhancing outreach efforts, streamlining recruitment processes, and addressing long-standing barriers and biases that hinder diversity and inclusion in clinical trials.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 8, 2024
With $45.8 billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. | AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014. But questions have emerged for one of the company's key growth drivers.
MedCity News
FEBRUARY 8, 2024
Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 8, 2024
After reaching a settlement with Minnesota’s attorney general, Eli Lilly can close the book on a yearslong lawsuit in the state. | The company will provide its insulin products at $35 per month and donate free insulin at 15 clinics over the next five years. Meanwhile, Minnesota's claims against Novo Nordisk and Sanofi remain ongoing.
MedCity News
FEBRUARY 8, 2024
Cano Health filed for bankruptcy this week — about three years after going public $4.4 billion SPAC merger. The industry reacted without surprise, with experts calling the bankruptcy a direct result of mismanagement, a quixotic growth strategy and poor market selection.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 8, 2024
Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.
Fierce Pharma
FEBRUARY 8, 2024
This week on “The Top Line,” we explore the most anticipated drug launches of 2024. | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.
pharmaphorum
FEBRUARY 8, 2024
Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.
Fierce Pharma
FEBRUARY 8, 2024
China has become the first country to sign off on Roche’s paroxysmal nocturnal hemo | China has become the first country to sign off on Roche’s paroxysmal nocturnal hemoglobinuria (PNH) drug crovalimab, a subcutaneous answer to AstraZeneca’s infused treatments Soliris and Ultomiris. Roche’s subsidiary Chugai Pharmaceutical, which developed crovalimab and owns its rights in Japan and Taiwan, announced the approval of the humanized complement inhibitor C5 monoclonal antibody.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
FEBRUARY 8, 2024
Vertex Pharmaceuticals’ once-daily small molecule vanzacaftor/tezacaftor/deutivacaftor (vanza triple) for cystic fibrosis (CF) has gleaned positive results in Phase III trials. The Phase III trials The clinical programme for the once daily vanza triple was comprised of two Phase III trials: SKYLINE 102 and SKYLINE 103, evaluating the efficacy of vanzacaftor (20 mg)/tezacaftor (100 mg)/deutivacaftor (250 mg) in cystic fibrosis patients 12 years and older with at least one F508del mutation or a m
Fierce Pharma
FEBRUARY 8, 2024
Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out. | Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out.
pharmaphorum
FEBRUARY 8, 2024
China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.
European Pharmaceutical Review
FEBRUARY 8, 2024
A report from Prophecy Market Insights on rapid microbiology testing has predicted that the market is anticipated to surpass $12.7 billion by 2034. Growth drivers of the global rapid microbiology testing market A rise in infectious diseases worldwide has increased demand for rapid and precise diagnostics. This has in turn accelerated growth of this market, the report stated.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
FEBRUARY 8, 2024
AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards an FDA BLA.
MedCity News
FEBRUARY 8, 2024
Companion care company Papa has created two programs for health plans: one that addresses social drivers of health and one that aims to improve health plans’ star ratings.
pharmaphorum
FEBRUARY 8, 2024
Autoimmune disease CAR-T therapy specialist Kyverna has upsized its IPO to $319m in another sign of an improving #biotech financing environment
MedCity News
FEBRUARY 8, 2024
MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.
pharmaphorum
FEBRUARY 8, 2024
BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies
Pharmaceutical Technology
FEBRUARY 8, 2024
Despite several ground-breaking developments, pharmaceutical and biotech companies are often reluctant to invest in cell and gene therapy.
pharmaphorum
FEBRUARY 8, 2024
Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team
Pharmaceutical Commerce
FEBRUARY 8, 2024
Data suggest that dosing of MariTide may be effectively tapered down and the drug may be taken less frequently over time compared with GLP-1 agonists such as Wegovy and Zepbound.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmaTimes
FEBRUARY 8, 2024
The committee has advised that the vaccine should be given to those at the highest risk
Pharmaceutical Technology
FEBRUARY 8, 2024
Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.
PharmaTimes
FEBRUARY 8, 2024
The cell could be a target for new immunotherapies for the chronic disease
Clarify Health
FEBRUARY 8, 2024
It is no exaggeration that the American healthcare industry faces a looming crisis: an increasing number of older adults with complex healthcare needs. Today, the 65-and-older population in the U.S. is just 13 percent but accounts for more than a third of healthcare expenditures. That number will increase significantly over the next 25 years. It’s estimated that by 2050, one-fifth of the total population in the United States will be aged 65 and older, and healthcare costs will rise at a simila
PM360
FEBRUARY 8, 2024
Elevate Healthcare and LivaNova USA, Inc. VNS Therapy is a Life-changer VNS (vagus nerve stimulation) Therapy is designed for people living with seizures despite trying multiple medications. The campaign helped showcase the ability of VNS patients to experience improved quality of life by illustrating everyday activities. The interactive visual aid enhanced the campaign by covering progressive intervention and seizure control.
PharmExec
FEBRUARY 8, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Jonathan Miller, General Counsel, US Hemp Roundtable, discusses recent efforts that urge the House Energy and Commerce Committee to expedite an FDA hearing on the hemp market.
PM360
FEBRUARY 8, 2024
Silver Winner – 21Grams and Alexion Pharmaceuticals ALPD (Alkaline Phosphatase Detectives) Campaign HCPs needed to be more suspicious of low ALP, the smoking gun in a hypophosphatasia diagnosis. We created a campaign that took HCPs inside the body for an immersive investigation to interview suspects, uncover evidence, and even upload their photo to see themselves in the campaign—a first in health. 21GRAMS TEAM MEMBERS: Tom Richards Global Chief Creative Officer Frank Mazzola Global Chief C
LEVO Health
FEBRUARY 8, 2024
As healthcare professionals (HCPs) become more adept at engaging with digital marketing content , pharmaceutical marketers find it crucial to recalibrate their strategies. This shift is about more than just keeping pace with technology. It’s about understanding and integrating into the digital routines of HCPs. By prioritizing specific HCP marketing strategies, pharma marketers can achieve more effective outreach and forge stronger, more enduring relationships with their target audience.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
338 
Let's personalize your content